Perspectives
perspectives
September 29th, 2026
Getting to First-in-Human Faster: What FDA’s New IND Pilot and NAMs Shift Mean for Sponsors
perspectives
September 21st, 2026
From Data to Decisions: Evaluating Bayesian Dynamic Borrowing Before Your Trial Begins
perspectives
September 11th, 2026
Navigating the Future of Clinical Trial Transparency: Balancing AI-Driven Anonymization with Human Oversight
perspectives
September 3rd, 2026
From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning
perspectives
August 27th, 2026
Risk-Based Data Management: Moving Beyond Traditional Data Cleaning
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know
perspectives
July 31st, 2026
FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid
perspectives
July 29th, 2026
From Signal to System: The Next Challenges for Psychedelic Therapies
perspectives
July 24th, 2026
FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors
perspectives
July 7th, 2026
Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data